1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Less than a month 'til #KidneyCancerAwarenessMonth kicks off in March!!! Join us as we raise awareness, share stories of resilience, and #OrangeUp !

kidneycancer.org/kidney-cancer-…

Follow along, share, or comment how you plan to get involved. 🧡⤵️

Standing room only 6 am for the NCTN ⁦⁦Alliance for Clinical Trials in Oncology⁩ ⁦SWOG Cancer Research Network⁩ ⁦ECOG-ACRIN Cancer Research Group⁩ ⁦NRG⁩ meeting at #GU24

Thank you Officer ⁦Stephanie Berg⁩ for organizing !

⁦Dana-Farber Lank Center for Genitourinary Oncology⁩

Financial toxicity is more than drug cost! When dx with cancer, half of pts stop or reduce saving for retirement, 15% sold homes or property, 25% borrowed from friends/family. We need to assess financial burden in #kidneycancer ! #GU24

Yup. Per the latest ICH E9(R1) recs we need to carefully consider our estimands during both RCT design & transporting inferences for shared decision-making. Stay tuned for upcoming summary from #IKCS23 think tank 👉 database.ich.org/sites/default/… Stephanie Berg Tian Zhang, MD, MHS @kidneycancer

Starting off Day 3 #GU24 with a phenomenal presentation by Toni Choueiri, MD showing OS survival with pembrolizumab in the adjuvant setting👉First trial to show an improvement of OS in the adjuvant setting
👉 Benefit across all sub groups
👉 38% reduction in the risk of death

✨👩🏽‍⚕️First ASCO 's women in #GU24 women networking lunch

So humbling and inspiring to meet some of the first women who paver the way for us

OncoAlert

✨ASCO #GU24 lady gang always ready to support each other!

Hematology & Oncology Women Physicians Group—HOWPG Stephanie Berg Tian Zhang, MD, MHS Rana McKay Tanya Dorff Andrea Apolo, M.D. Cristiane D Bergerot Maite Bourlon Elizabeth Plimack MD Ulka Vaishampayan Laurence Albiges Shilpa Gupta Cris KCCure Gretchen Vaughan Laura Bukavina…

‼️✴️ Ready or not here we go! Day 2 #GU24 for #urothelial carcinoma! ‼️

Excitedly waiting for rockstar Amanda Nizam, MD’s stellar oral talk!

Kicking off #GU24 is our newly elected ASCO president, Dr. Eric Small! As a member of the small group that created this meeting, he's the perfect person to highlight its growth. It's hard to believe that 20y have passed since #TAX327 /SWOG Cancer Research Network studies affirming docetaxel for…

#EricSmall Lynn M. Schuchter, MD, FASCO -elect highlights the history of the #GUsymposium meeting, pays homage to GU giant #NickVogelzang . Developmental therapies & state of science in 2005 — what a long way we have come in 20 yrs & more to come! OncoAlert @ASCO #GU24

How do we help patients with nonclear cell #kidneycancer identify 1L study opportunities? Admittedly these studies are not open universally but today in clinic & over past several weeks, ran into several pts who felt remiss about not having been able to consider 1L studies prior…

Excited to get going with Natalie Johnson, MS for this #WomenInRCC session on harnessing stress for healthcare leaders! #gu24

Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by @ucsf team w/Rahul Aggarwal reports. ow.ly/XWLl50QtQ80

A comprehensive review on 'Mechanisms of #tyrosine #kinase #inhibitor resistance in #renal #cell #carcinoma ' by Dr. Arpita Desai Arpita Desai from UC San Francisco and her team
📚 Free access: oaepublish.com/articles/cdr.2…
🔗Download: oaepublish.com/articles/downl…
Don't miss this insightful review!

What a great team to be part of as featured voices ASCO #GU24 ! Looking forward to amplifying messages from Dena Battle David Braun Shuchi Gulati MD Sophia Kamran, MD Amanda Nizam, MD Ruchika Talwar Karine Tawagi MD Yüksel Ürün!
Give us all a follow & see y’all soon in SF!

JUST IN: U.S. FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors!

A great day for the field and a new option for our Kidney Cancer patients!!!!

Via ASCO #FDAAlerts OncoAlert

Study presented at ESMO - Eur. Oncology #ESMO3 by…

More great learning from Jiaoti Huang DukePathDept — glypican3 (GPC3) as an emerging target for #prostatecancer !
DAVA Oncology DCI Center for Prostate & Urologic Cancers Duke Cancer #GUSummit23